Y-mAbs Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview

Y-mAbs Therapeutics

27/02/2024 22:52

* Y-mAbs Therapeutics Inc  YMAB.OQ   YMAB.O  is expected
to show a
fall in quarterly revenue when it reports  results on February
29 for the period ending December 31 2023
    * The New York City-based  company is expected to report a
33.4% decrease in revenue to $20.955 million from $31.45 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Y-mAbs Therapeutics Inc
is for
a loss of 20 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Y-mAbs
Therapeutics Inc is $18.00​, above​ its last closing price
of $16.50. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.18       -0.19      -0.18     Beat    3.7
 Jun. 30 2023  -0.24       -0.24      -0.14     Beat    42.1
 Mar. 31 2023  -0.32       -0.32      -0.15     Beat    52.9​
 Dec. 31 2022  -0.44       -0.46      0.03      Beat    106.6
 ​​Sep.        -0.71       -0.71      -0.63     Beat    11.3
 30 2022                                                
 Jun. 30 2022  -0.67       -0.67      -0.94     Missed  -41.2​
 Mar. 31 2022  -0.73       -0.72      -0.64     Beat    10.7
 Dec. 31 2021  -0.70       -0.70      -0.85     Missed  -20.7
 This summary was machine generated February 27 at 22:52 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)